| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The primary target of beta-Casomorphin 7 is the μ-opioid receptor. It acts as an agonist at this receptor. It has an IC₅₀ of 14 μM for binding to opioid receptors. Its activity is selective for the μ-opioid receptor, as indicated by the GPI/MVD ratio for bovine β-casomorphin-7. By activating this receptor, it can modulate pain perception, gastrointestinal function, and other opioid-mediated effects.
|
|---|---|
| ln Vitro |
After 8 hours of treatment, mucin secretion in DHE cells is stimulated by bovine beta-casomorphin (0.1 μM; 30 minutes to 24 hours) [2]. Increased rMuc2 and rMuc3 mRNA levels are induced by β-casomorphin, bovine (0.1 μM; 24 hours) [2]. β-Casomorphin, bovine does not modify rMuc1, rMuc4, and rMuc5AC expression [2]. Human HT29-MTX cells are stimulated to secrete mucin and express MUC5AC by bovine β-casomorphin (0.1 μM; 24 hours) [2].
In vitro, beta-Casomorphin 7 exhibits opioid activity. It binds to opioid receptors with an IC₅₀ of 14 μM. It functions as a μ-opioid receptor agonist. Its activity can be assessed in standard opioid receptor binding and functional assays. It regulates the secretion and expression of gastrointestinal mucins through a μ-opioid pathway. These in vitro activities confirm its role as a bioactive peptide. |
| ln Vivo |
Bovine β-casomorphin (7.5×10−6 mol/day/kg; gavage; for 30 days) raises plasma insulin and lowers plasma glucagon in diabetic rats [3]. β-Casomorphin, bovine (7.5×10−6 mol/day/kg; ig; for 30 days) modifies the alterations of SOD, GPx, T-AOC, MDA and H2O2 in the kidneys of diabetic rats [3]. Bovine β-casomorphin (7.5×10−6 mol/day/kg; gavage; for 30 days) lowered MDA (significant) and H2O2 (non-significant) levels in the kidney compared with diabetic rats [3]. β-Casomorphin, bovine (7.5×10−6 mol/day/kg; ig; for 30 days) reduced the high-glucose-induced decrease in SOD and GPx activities and the increase in MDA content in NRK-52E cells [
In vivo, beta-Casomorphin 7 has been studied for its effects on the gastrointestinal tract. It regulates the secretion and expression of gastrointestinal mucins through a μ-opioid pathway. As an exogenous opioid peptide, it may exert effects similar to endogenous opioids, such as modulation of pain and gastrointestinal motility. Its in vivo effects are areas of ongoing research. |
| Enzyme Assay |
In vitro receptor binding studies for beta-Casomorphin 7 measure its affinity for opioid receptors. Radioligand displacement assays are performed using membrane preparations from cells expressing the μ-opioid receptor. The peptide competes with a labeled opioid ligand for binding, and the IC₅₀ or Ki value is determined from the competition curve. Selectivity for the μ-opioid receptor over other opioid receptor subtypes can also be assessed. These protocols are for research purposes only.
|
| Cell Assay |
In vitro cell-based assays for beta-Casomorphin 7 evaluate its functional activity at the μ-opioid receptor. Cells expressing the μ-opioid receptor are treated with the peptide, and receptor activation is measured by downstream signaling, such as inhibition of cAMP accumulation or activation of G-protein-coupled inwardly rectifying potassium (GIRK) channels. Its ability to stimulate mucin secretion can be studied in gastrointestinal epithelial cell lines. Standard cell culture techniques are used.
|
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat (200 g±10 g) [3]
Doses: 7.5×10−6 mol/day/kg Route of Administration: po (oral gavage); 30 days Experimental Results: Diabetic rats Plasma insulin increases and plasma glucagon decreases. In vivo animal studies for beta-Casomorphin 7 would typically involve models of gastrointestinal function or pain. For example, its effect on mucin secretion could be studied in rodent models by administering the peptide and measuring mucin levels in intestinal tissue or lavage fluid. Its analgesic effects could be assessed using standard pain models like the tail-flick test. All procedures must comply with institutional animal care guidelines. |
| ADME/Pharmacokinetics |
The pharmacokinetic properties of beta-Casomorphin 7 are not characterized in the provided literature. As a peptide, it would be susceptible to proteolytic degradation in the gastrointestinal tract and in plasma. Its stability, half-life, and bioavailability would be important factors for its in vivo activity. It is a research tool for studying opioid biology.
|
| Toxicity/Toxicokinetics |
The toxicity profile of beta-Casomorphin 7 is not detailed. It is classified for research use only and not for human consumption. As a bioactive peptide, its potential toxicity would be related to its opioid activity. Standard safety precautions for handling peptides should be followed.
|
| References | |
| Additional Infomation |
Additional information: beta-Casomorphin 7 has the CAS number 72122-62-4. Its sequence is Tyr-Pro-Phe-Pro-Gly-Pro-Ile. It is a bovine beta-casomorphin. It acts as a μ-opioid receptor agonist with an IC₅₀ of 14 μM for opioid receptor binding. It is a research tool for studying opioid receptor biology and the effects of dietary peptides. This product is for research use only and is not approved for clinical or therapeutic applications.
|
| Molecular Formula |
C41H55N7O9
|
|---|---|
| Molecular Weight |
789.9169
|
| Exact Mass |
789.406
|
| CAS # |
72122-62-4
|
| Related CAS # |
β-Casomorphin, bovine TFA
|
| PubChem CID |
121946
|
| Appearance |
White to off-white solid powder
|
| Density |
1.32g/cm3
|
| Boiling Point |
1170.5ºC at 760 mmHg
|
| Flash Point |
661.7ºC
|
| Index of Refraction |
1.607
|
| LogP |
2.38
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
57
|
| Complexity |
1450
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)N
|
| InChi Key |
RKYJTDSQXOMDAD-JKXTZXEVSA-N
|
| InChi Code |
InChI=1S/C41H55N7O9/c1-3-25(2)35(41(56)57)45-38(53)32-13-7-19-46(32)34(50)24-43-36(51)31-12-8-21-48(31)40(55)30(23-26-10-5-4-6-11-26)44-37(52)33-14-9-20-47(33)39(54)29(42)22-27-15-17-28(49)18-16-27/h4-6,10-11,15-18,25,29-33,35,49H,3,7-9,12-14,19-24,42H2,1-2H3,(H,43,51)(H,44,52)(H,45,53)(H,56,57)/t25-,29-,30-,31-,32-,33-,35-/m0/s1
|
| Chemical Name |
(2S,3S)-2-[[(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~126.60 mM)
H2O : ≥ 50 mg/mL (~63.30 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 25 mg/mL (31.65 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2660 mL | 6.3298 mL | 12.6595 mL | |
| 5 mM | 0.2532 mL | 1.2660 mL | 2.5319 mL | |
| 10 mM | 0.1266 mL | 0.6330 mL | 1.2660 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03513991 | Completed | Other: Infant formula | Breast Feeding of Healthy Full Term Infants
Formula Feeding of Healthy Full Term Infants Growth & Development |
Universidad Autonoma de Queretaro | 2016-02-15 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
